Departments of Psychology, University of South Florida, Tampa, FL, United States of America.
Molecular Pharmacology & Physiology, University of South Florida, Tampa, FL, United States of America.
PLoS One. 2019 Jan 17;14(1):e0205138. doi: 10.1371/journal.pone.0205138. eCollection 2019.
Statins have been prescribed for primary prevention of cardiovascular disease (CVD) for nearly 3 decades. Throughout this period key opinion leaders in the field have been dismayed by the high rate of non-adherence of patients to follow their statin regimen. Hope et al., [1] have addressed this issue by providing a systematic review of research on predictors of statin adherence for primary prevention of CVD. However, their review does not address the ongoing debate as to whether statin treatment is warranted for primary prevention of CVD, nor does it adequately address concerns regarding adverse effects of statins. We have therefore written a commentary which provides a broader perspective on the benefits versus harms of statin therapy. Our perspective of the literature is that non-adherence to statin treatment for primary prevention of CVD is justified because the meager benefits are more than offset by the extensive harms.
他汀类药物已被用于心血管疾病（CVD）的一级预防近 30 年。在此期间，该领域的主要意见领袖对患者不遵守他汀类药物治疗方案的高不依从率感到沮丧。Hope 等人[1]通过对 CVD 一级预防中他汀类药物依从性预测因素的研究进行系统评价，解决了这一问题。然而，他们的综述并未涉及关于他汀类药物治疗是否适用于 CVD 一级预防的持续争论，也没有充分解决他汀类药物的不良反应问题。因此，我们撰写了一篇评论，从他汀类药物治疗的利弊角度提供了更广泛的观点。我们对文献的看法是，CVD 一级预防中不依从他汀类药物治疗是合理的，因为他汀类药物治疗的微薄益处远远超过了其广泛的危害。
